In five days, on November 17, at 7:30pm (Eastern Standard Time / New York), the Chondrosarcoma Foundation will host its first Virtual Dialogue: Straight Talk About Chondrosarcoma. We are fortunate to be bringing together a large diverse group…
News
In five days, on November 17, at 7:30pm (Eastern Standard Time / New York), the Chondrosarcoma Foundation will host its first Virtual Dialogue: Straight Talk About Chondrosarcoma. We are fortunate to be bringing together a large diverse group…
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma William D. Tap, MD1,2; Victor M. Villalobos, MD, PhD3; Gregory M. Cote, MD, PhD4; Howard Burris, MD5; Filip Janku, MD,…
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells Luyuan Li,
Ana C. Paz,
Breelyn A. Wilky,
Britt Johnson,
Karina…
Straight Talk About Chondrosarcoma
A Virtual Dialogue (Via Zoom)
Tuesday, November 17, 2020
7:30pm – 8:30pm EST www.csfshayna.org/straight-talk-registration/ Please share and circulate this invitation to all Oncologists and Sarcoma…
The Biology and Management of Cartilaginous Tumors: A Role For Targeting Isocitrate Dehydrogenase Gabriel Tinoco, MD, Breelyn A. Wilky, MD, Ana Paz-Mejia, MS, Andrew Rosenberg, MD, Jonathan C. Trent, MD, PhD Jonathan Trent, M.D., Ph.D. is a world…
Sarcomas: Evidence-Based Diagnosis and Management
Jonathan C. Trent, Andrew E. Rosenberg, Raphael Pollock, Thomas F. Delaney
Springer Publishing Company, Incorporated, 2020 – Medical – 434 pages Jonathan Trent, M.D.,Ph.D. is the leader of the…